Medisix Therapeutics Pte. Ltd.
MediSix Therapeutics Pte. Ltd. is a Singapore-based immune cell engineering and cell therapy company and an IASO Biotechnology subsidiary.
Listing updated
About Medisix Therapeutics Pte. Ltd.
MediSix Therapeutics Pte. Ltd. is a Singapore-based immune cell engineering and cell therapy company and an IASO Biotechnology subsidiary. It develops T-cell therapies using its proprietary PEBL (Protein Expression Blocker) technology platform, which traps specific proteins inside the cell to prevent their expression on the cell surface. PEBL-CAR is designed to avoid fratricide without gene editing. The company was founded in 2016 by Professor Dario Campana.
MediSix's stated mission is to develop effective T-cell therapies by leveraging proprietary technologies that improve and expand T-cell function, with the belief that T-cell therapies will change the treatment of cancer and autoimmune diseases. Its capabilities span scientific innovation, cell, protein and antibody engineering, translational medicine and clinical expertise.
- Category
- Research and product development
- Location
- Singapore
- Website
- medisixtx.com
Summary written with AI from public business data. Disclaimer
Products & services
- PEBL technology platform
- PEBL-CAR T-cell platform
- T-cell therapies for cancer and autoimmune diseases
- Immune cell engineering and cell therapy
Tap a product to find other suppliers of it.
Location
Quick facts
- Business name
- Medisix Therapeutics Pte. Ltd.
- What it supplies
- Medisix Therapeutics Pte. Ltd. is listed under Research and product development.
- Category
- Research and product development
- Location
- Singapore
- Listed products and services
- PEBL technology platform, PEBL-CAR T-cell platform, T-cell therapies for cancer and autoimmune diseases, Immune cell engineering and cell therapy. (Summarised with AI from public business data.)
- How to contact
- Website and an enquiry form on this page.
- Listing last updated